| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/13/1999 | US5922341 Administering an antidepressant, antiserotonin agent or adrenergic blocking agent |
| 07/13/1999 | US5922340 Administering with glucocorticoid; sustained release |
| 07/13/1999 | US5922321 Prostate-specific kallikrein |
| 07/13/1999 | US5922318 Drug protein |
| 07/13/1999 | US5922306 Inhalants dispersion comprising tetrafluoroethane/1,1,1,2-/ propellant, drug particles precoated with surfactant, the drug formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate for respiratory system disorders |
| 07/13/1999 | US5922302 Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates |
| 07/13/1999 | US5922253 Production scale method of forming microparticles |
| 07/13/1999 | CA2258445A1 Compositions for the reduction of scarring |
| 07/13/1999 | CA2131477C Cosmetic or dermatological composition containing an oil-in-water emulsion made of oily globules coated with a stratified liquid crystalline layer |
| 07/13/1999 | CA2044154C Method of assaying d-vanillylmandelic acid, and reagent and kit therefor |
| 07/08/1999 | WO1999034004A2 Metastatic breast and colon cancer regulated genes |
| 07/08/1999 | WO1999033994A1 Modified deacetoxycephalosporin c synthase (daocs) and x-ray structure |
| 07/08/1999 | WO1999033989A2 Rantes mutants and therapeutic applications thereof |
| 07/08/1999 | WO1999033981A2 Human signal peptide-containing proteins |
| 07/08/1999 | WO1999033963A1 Metastatic cancer regulated gene |
| 07/08/1999 | WO1999033870A2 Human regulatory proteins |
| 07/08/1999 | WO1999033815A1 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors |
| 07/08/1999 | WO1999033483A1 Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| 07/08/1999 | WO1999033477A1 Drug-directed mutagenesis/drug-driven selection for lethal mutants |
| 07/08/1999 | WO1999033355A2 Fat blend |
| 07/08/1999 | WO1999023109A3 A method for mapping the active sites bound by enzymes that covalently modify substrate molecules |
| 07/08/1999 | WO1999021574A3 Enhancement of morphogen activity |
| 07/08/1999 | WO1999016406A3 Therapeutic method |
| 07/08/1999 | WO1999009967B1 Cholesterol-lowering therapy |
| 07/08/1999 | WO1999004265A9 Cancer associated nucleic acids and polypeptides |
| 07/08/1999 | WO1998045711A3 Assay for ligands to tyrosine kinase receptors |
| 07/08/1999 | CA2316401A1 Modified deacetoxycephalosporin c synthase (daocs) and x-ray structure |
| 07/08/1999 | CA2316079A1 Human regulatory proteins |
| 07/08/1999 | CA2315617A1 Human signal peptide-containing proteins |
| 07/07/1999 | EP0927763A2 Novel aroA |
| 07/07/1999 | EP0927257A2 Human protein kinases |
| 07/07/1999 | EP0927196A1 Polymers containing polysaccharides such as alginates or modified alginates |
| 07/07/1999 | EP0927036A1 Transdermal therapeutical approach involving a combination of active substances containing oestriol |
| 07/07/1999 | EP0927024A2 Device and method for treating ophthalmic diseases |
| 07/07/1999 | EP0926955A1 Conjugates useful in the treatment of prostate cancer |
| 07/07/1999 | EP0828492A4 Method for preventing intervention-associated stenosis following non-bypass, invasive interventions |
| 07/07/1999 | EP0701438B1 Gaba-ergic modulation of eye growth |
| 07/07/1999 | EP0636027B1 Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| 07/07/1999 | CN1222053A Low PH acidic compns. |
| 07/07/1999 | CN1221608A Synergistic combination of AIDS antiviral compounds and HIV inhibitor |
| 07/06/1999 | US5919904 Response regulator polypeptides; screening for bactericides |
| 07/06/1999 | US5919826 Synergistic mixture of tramadol and asparatic acid, n-methyl-receptor antagonist |
| 07/06/1999 | US5919821 Plant extract |
| 07/06/1999 | US5919816 Administering drug with protective agent |
| 07/06/1999 | US5919802 Methods of preventing and/or treating temporal lobe epilepsy |
| 07/06/1999 | US5919795 Atherosclerosis therapy |
| 07/06/1999 | US5919781 Use of NK-1 receptor antogonists for treating substance use disorders |
| 07/06/1999 | US5919767 Adjust protein concnetration in muscles |
| 07/06/1999 | US5919763 IL-6/SIL-6R complex for promotion of liver functions |
| 07/06/1999 | US5919760 Method for treating acute and severe diarrhea |
| 07/06/1999 | US5919755 Medical use of heme products |
| 07/06/1999 | US5919664 For screening for antibacterial compounds |
| 07/06/1999 | US5919660 Human requiem |
| 07/06/1999 | US5919659 Polynucleotide |
| 07/06/1999 | US5919465 Methods for augmenting immunological responses through the administration of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) |
| 07/06/1999 | US5919464 Controlling cell differentiation |
| 07/06/1999 | US5919456 IL-13 receptor specific chimeric proteins |
| 07/06/1999 | US5919455 Non-antigenic branched polymer conjugates |
| 07/06/1999 | US5919444 Method for decreasing severity of acute and chronic pancreatitis |
| 07/06/1999 | US5919438 Combinatory immixture of (a) at least one antifungal agent and (b) at least one halogenated antibacterial agent other than a macrolide or pyranoside |
| 07/06/1999 | CA2131991C Treatment of migraine |
| 07/06/1999 | CA2130762C Treatment of disease and conditions associated with macrophage infiltration |
| 07/06/1999 | CA1340633C Method and therapeutic compositions for the treatment of myocardial infarction |
| 07/05/1999 | WO1999038976A2 Human growth factor homologs |
| 07/05/1999 | CA2317812A1 Human growth factor homologs |
| 07/01/1999 | WO1999032637A1 Human signal transduction serine/threonine kinase |
| 07/01/1999 | WO1999032635A1 Acetyl-coa-carboxylase from candida albicans |
| 07/01/1999 | WO1999032620A1 Insulin-like growth factor binding protein fragments and the utilization thereof |
| 07/01/1999 | WO1999032615A1 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof |
| 07/01/1999 | WO1999032610A1 Human nucleotide pyrophosphohydrolase-2 |
| 07/01/1999 | WO1999032175A1 Method and device for in-situ formulation of a medicinal solution for parenteral application |
| 07/01/1999 | WO1999032150A1 Ace inhibitor-mmp inhibitor combinations |
| 07/01/1999 | WO1999032148A1 Methods and compositions for inhibiting tumor cell growth |
| 07/01/1999 | WO1999032127A1 Angiostatic agents and compositions for controlling ocular hypertension |
| 07/01/1999 | WO1999032119A1 Opioid agonist/antagonist combinations |
| 07/01/1999 | WO1999032114A1 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
| 07/01/1999 | WO1999032101A1 Treatment of glc1a glaucoma with non-steroidal glucocorticoid antagonists |
| 07/01/1999 | WO1999032098A2 Combination of a ramba and a tocopherol |
| 07/01/1999 | WO1999032093A1 Oral pharmaceutical pulsed release dosage form |
| 07/01/1999 | WO1999032077A1 Use of amino phenol amide derivatives as depigmentation agents |
| 07/01/1999 | WO1999032072A1 Compositions and methods for treatment of alopecia |
| 07/01/1999 | WO1999031987A1 Topical carbamazepine formulations and methods of use |
| 07/01/1999 | WO1999031982A1 Transvascular delivery of a composition to an extravascular tissue of a mammal |
| 07/01/1999 | WO1999031969A2 Transgenic animal model for degenerative diseases of cartilage |
| 07/01/1999 | WO1999024051A3 Application of vasopressin antagonists for treating disturbances or illnesses of the inner ear |
| 07/01/1999 | WO1999020747A3 HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS |
| 07/01/1999 | WO1999020223A3 Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive |
| 07/01/1999 | WO1999015167A3 Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer |
| 07/01/1999 | DE19757414A1 Fettmischung Fatblend |
| 07/01/1999 | DE19757250A1 Insulin-like growth factor binding protein und seine Verwendung Insulin-like growth factor binding protein and its use |
| 07/01/1999 | DE19757224A1 Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation Method and apparatus for in-situ formulation of a medicinal substance solution for parenteral administration |
| 07/01/1999 | DE19756235A1 Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide New piperidinylsubstituierte pyridylalkane alkene and -alkincarbonsäureamide |
| 07/01/1999 | CA2315974A1 Insulin-like growth factor binding protein fragments and the utilization thereof |
| 07/01/1999 | CA2315788A1 Human nucleotide pyrophosphohydrolase-2 |
| 07/01/1999 | CA2315037A1 Methods and compositions for inhibiting tumor cell growth |
| 07/01/1999 | CA2314905A1 Transvascular delivery of a composition to an extravascular tissue of a mammal |
| 07/01/1999 | CA2314868A1 Topical carbamazepine formulations and methods of use |
| 07/01/1999 | CA2314357A1 Transgenic animal model for degenerative diseases of cartilage |
| 07/01/1999 | CA2313232A1 Treatment of glc1a glaucoma with non-steroidal glucocorticoid antagonists |
| 07/01/1999 | CA2305436A1 Ace inhibitor-mmp inhibitor combinations |